About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
September 2023 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Twitter List
Legislative Tracking Tools
Category Archives: Marketing
Pharma Sales Slowdown
IMS, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries released the annual "U.S. Pharmaceutical Market Performance Review" which found that pharmaceutical market growth slowed from 8% in 2006 to 3.8% in 2007. According … Continue reading
Posted in Marketing
Comments Off on Pharma Sales Slowdown
If a Tree Falls in the Forest….
If a tree falls in the forest, and almost no one notices, did the tree almost not fall? Pharmaceutical Executive noticed, but I didn’t notice anyone else notice. I’m talking about the long-proposed user fee program for the FDA’s Division … Continue reading
Posted in DTC Advertising, FDA Policy, Marketing
2 Comments
India Grants Patent to AIDS Drug
One of the many confounding things about the AIDS epidemic is the radical shift of the HIV disease burden to populations of countries with the least ability to payfor therapy. That creates a number of dilemmas and conundrums. One, those … Continue reading
Posted in Marketing
Comments Off on India Grants Patent to AIDS Drug
New DTC Oversight Powers Given FDA – Show Me the Money!
I was fascinated to read the RPM Report analysis of the new system that will emerge when the new FDA bill is signed into law. A new user fee program for review of DTC ads will exist that allows the … Continue reading
Posted in DTC Advertising, FDA Policy, Legislation, Marketing
1 Comment
PSAs and YouTube – Another Installment on Social Media
I have written several postings in the past on uses of social media by pharmaceuticals. Just last week, I had a posting on Fard Johnmar’s excellent White Paper on the legal aspects of social media by pharmaceuticals. One idea that … Continue reading
Posted in Marketing, Social Media
Comments Off on PSAs and YouTube – Another Installment on Social Media